AKTX

$0.00

(

0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Akari Therapeutics PLC

NASDAQ | AKTX

0.43

USD

$0.00

(

0.00%

)

At Close (As of Nov 28, 2025)

$16.96M

Market Cap

0

P/E Ratio

0

EPS

$1.73

52 Week High

$0.41

52 Week Low

HEALTHCARE

Sector

AKTX Chart

Recent Chart
Price Action

AKTX Technicals

Tags:

AKTX Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$14K
Total Revenue $0
Cost Of Revenue $14K
Costof Goods And Services Sold $14K
Operating Income -$22M
Selling General And Administrative $9.7M
Research And Development $7M
Operating Expenses $22M
Investment Income Net -
Net Interest Income -$236K
Interest Income $8K
Interest Expense $244K
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $14K
Income Before Tax -$20M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$20M
Comprehensive Income Net Of Tax -
Ebit -$20M
Ebitda -$20M
Net Income -$20M

Revenue & Profitability

Earnings Performance

AKTX Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $51M
Total Current Assets $3M
Cash And Cash Equivalents At Carrying Value $2.6M
Cash And Short Term Investments $2.6M
Inventory -
Current Net Receivables $201K
Total Non Current Assets $48M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets $39M
Intangible Assets Excluding Goodwill $39M
Goodwill $8.4M
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $152K
Other Non Current Assets -
Total Liabilities $28M
Total Current Liabilities $20M
Current Accounts Payable $12M
Deferred Revenue -
Current Debt -
Short Term Debt $3.3M
Total Non Current Liabilities $8.4M
Capital Lease Obligations -
Long Term Debt -
Current Long Term Debt $3.3M
Long Term Debt Noncurrent -
Short Long Term Debt Total $3.3M
Other Current Liabilities $4.2M
Other Non Current Liabilities $383K
Total Shareholder Equity $22M
Treasury Stock -
Retained Earnings -$247M
Common Stock $5.3M
Common Stock Shares Outstanding $12K

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$13M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $14K
Capital Expenditures $0
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment $382K
Cashflow From Financing $11M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$20M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$14K
Total Revenue $0
Cost Of Revenue $14K
Costof Goods And Services Sold $14K
Operating Income -$22M
Selling General And Administrative $9.7M
Research And Development $7M
Operating Expenses $22M
Investment Income Net -
Net Interest Income -$236K
Interest Income $8K
Interest Expense $244K
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $14K
Income Before Tax -$20M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$20M
Comprehensive Income Net Of Tax -
Ebit -$20M
Ebitda -$20M
Net Income -$20M

AKTX News

AKTX Profile

Akari Therapeutics PLC Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Akari Therapeutics PLC is a London-based clinical-stage biopharmaceutical company dedicated to developing innovative therapies for autoinflammatory diseases by targeting the complement and leukotriene pathways. The company boasts a diverse pipeline of drug candidates aimed at addressing significant unmet medical needs and enhancing patient outcomes. With a commitment to leveraging its scientific expertise through strategic partnerships, Akari Therapeutics is well-positioned to effectively navigate the complexities of clinical development and deliver transformative therapies to market.

LPTX
+368.57%
$2.05
VHAI
0.00%
$0.00
BYND
+19.00%
$1.02
INHD
-16.32%
$0.22
ZYXI
+115.62%
$1.59
VINE
+10.76%
$0.39
ONDS
-2.36%
$8.24
AMBR
+56.32%
$2.47
BITF
+11.91%
$3.10
PLUG
+1.53%
$1.98
KTTA
+61.79%
$1.71
IPG
-1.95%
$24.57
ASST
+1.80%
$1.13
AXDX
-61.36%
$0.03
INTC
+2.73%
$36.81
GPUS
+15.78%
$0.33
GOOGL
-1.07%
$319.95
SPRC
-9.01%
$2.22
ADAP
-15.14%
$0.05
YGMZ
-34.15%
$0.12
WULF
+6.45%
$14.84
HOOD
+10.92%
$128.20
RUBI
-8.19%
$0.21
F
+0.15%
$13.19
SOND
-23.45%
$0.12
RMBL
+60.50%
$3.21
TLRY
+4.76%
$1.03
BTBT
+2.65%
$2.32
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
GRAB
+1.52%
$5.32
SRM
+53.27%
$10.30
PFE
-0.03%
$25.71
AGNC
+1.53%
$10.56
BTG
+3.23%
$4.47
BAC
+0.97%
$52.99
CCL
-1.12%
$25.43
BIYA
+11.34%
$0.28
SNAP
-0.39%
$7.61
TWOH
0.00%
$0.00
ACHR
+1.49%
$7.49
CRWV
+4.20%
$74.29
WLGS
-5.57%
$0.04
MTSR
-0.35%
$70.50
T
-0.15%
$25.82
AEHL
+8.43%
$3.47
IREN
+2.06%
$48.45
MSFT
+1.78%
$485.50
ITUB
+3.23%
$7.66
NVDA
-1.02%
$178.41
DEFT
+20.86%
$1.39
AFMD
-34.94%
$0.18
HBI
-0.45%
$6.59
HPQ
-1.39%
$23.98
PLTZ
-2.62%
$7.43
APLD
+5.05%
$24.94
MNDR
+39.47%
$2.65
SMCI
+1.07%
$32.83
BABA
+0.37%
$157.60
VSA
-14.30%
$0.12
NVTS
+3.86%
$8.34
OSCR
+8.54%
$18.16
SOUN
-1.00%
$11.82
HL
+6.60%
$15.97
HPE
+0.79%
$21.53
GRYP
-10.38%
$1.38
NGD
+6.66%
$7.84
MODV
-25.22%
$0.43
AMCR
+1.29%
$8.62
KSS
+7.49%
$24.10
BTE
-0.31%
$3.16
RR
-3.35%
$3.46
CMND
-3.06%
$0.15
NVO
+3.50%
$48.71
KDLY
+7.20%
$0.49
NAKA
+7.20%
$0.49
TMC
+7.36%
$5.83
CRCL
+3.60%
$72.64
PTCT
+4.00%
$86.25
PBR
+0.31%
$12.66
VZ
+0.71%
$40.88
MRVL
+5.14%
$87.72
ECDA
-3.66%
$0.53
JBLU
+3.43%
$4.52
SAND
-6.04%
$12.12
CLSK
+11.96%
$15.05
DKNG
+1.67%
$32.20
CWVX
+9.25%
$5.31
LEN
+0.15%
$131.28
MBOT
+21.80%
$2.29
SHOT
-74.37%
$0.39
LYFT
+2.69%
$20.16
QS
+1.85%
$12.08
ASBP
+2.76%
$0.10
ZAPP
-46.30%
$0.15
NBIS
+6.53%
$94.69
CYPH
+14.18%
$1.69
FCX
+2.62%
$42.15
AUR
+3.31%
$4.05
AMC
+1.76%
$2.30
LPTX
+368.57%
$2.05
VHAI
0.00%
$0.00
BYND
+19.00%
$1.02
INHD
-16.32%
$0.22
ZYXI
+115.62%
$1.59
VINE
+10.76%
$0.39
ONDS
-2.36%
$8.24
AMBR
+56.32%
$2.47
BITF
+11.91%
$3.10
PLUG
+1.53%
$1.98
KTTA
+61.79%
$1.71
IPG
-1.95%
$24.57
ASST
+1.80%
$1.13
AXDX
-61.36%
$0.03
INTC
+2.73%
$36.81
GPUS
+15.78%
$0.33
GOOGL
-1.07%
$319.95
SPRC
-9.01%
$2.22
ADAP
-15.14%
$0.05
YGMZ
-34.15%
$0.12
WULF
+6.45%
$14.84
HOOD
+10.92%
$128.20
RUBI
-8.19%
$0.21
F
+0.15%
$13.19
SOND
-23.45%
$0.12
RMBL
+60.50%
$3.21
TLRY
+4.76%
$1.03
BTBT
+2.65%
$2.32
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
GRAB
+1.52%
$5.32
SRM
+53.27%
$10.30
PFE
-0.03%
$25.71
AGNC
+1.53%
$10.56
BTG
+3.23%
$4.47
BAC
+0.97%
$52.99
CCL
-1.12%
$25.43
BIYA
+11.34%
$0.28
SNAP
-0.39%
$7.61
TWOH
0.00%
$0.00
ACHR
+1.49%
$7.49
CRWV
+4.20%
$74.29
WLGS
-5.57%
$0.04
MTSR
-0.35%
$70.50
T
-0.15%
$25.82
AEHL
+8.43%
$3.47
IREN
+2.06%
$48.45
MSFT
+1.78%
$485.50
ITUB
+3.23%
$7.66
NVDA
-1.02%
$178.41
DEFT
+20.86%
$1.39
AFMD
-34.94%
$0.18
HBI
-0.45%
$6.59
HPQ
-1.39%
$23.98
PLTZ
-2.62%
$7.43
APLD
+5.05%
$24.94
MNDR
+39.47%
$2.65
SMCI
+1.07%
$32.83
BABA
+0.37%
$157.60
VSA
-14.30%
$0.12
NVTS
+3.86%
$8.34
OSCR
+8.54%
$18.16
SOUN
-1.00%
$11.82
HL
+6.60%
$15.97
HPE
+0.79%
$21.53
GRYP
-10.38%
$1.38
NGD
+6.66%
$7.84
MODV
-25.22%
$0.43
AMCR
+1.29%
$8.62
KSS
+7.49%
$24.10
BTE
-0.31%
$3.16
RR
-3.35%
$3.46
CMND
-3.06%
$0.15
NVO
+3.50%
$48.71
KDLY
+7.20%
$0.49
NAKA
+7.20%
$0.49
TMC
+7.36%
$5.83
CRCL
+3.60%
$72.64
PTCT
+4.00%
$86.25
PBR
+0.31%
$12.66
VZ
+0.71%
$40.88
MRVL
+5.14%
$87.72
ECDA
-3.66%
$0.53
JBLU
+3.43%
$4.52
SAND
-6.04%
$12.12
CLSK
+11.96%
$15.05
DKNG
+1.67%
$32.20
CWVX
+9.25%
$5.31
LEN
+0.15%
$131.28
MBOT
+21.80%
$2.29
SHOT
-74.37%
$0.39
LYFT
+2.69%
$20.16
QS
+1.85%
$12.08
ASBP
+2.76%
$0.10
ZAPP
-46.30%
$0.15
NBIS
+6.53%
$94.69
CYPH
+14.18%
$1.69
FCX
+2.62%
$42.15
AUR
+3.31%
$4.05
AMC
+1.76%
$2.30
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.